Brief: ZimVie Q2 Adjusted EPS USD 0.26

Zimvie

30/07/2025 21:05

Overview

ZimVie Q2 sales of $116.7 mln beat analyst expectations, per LSEG data

Adjusted EPS of $0.26 beats analyst estimates, per LSEG data

Co had previously agreed to be acquired by ARCHIMED for $19.00 per share in cash

Outlook

ZimVie withdraws fiscal 2025 guidance due to pending acquisition

Transaction with ARCHIMED expected to close by year-end 2025

Result Drivers

RESTRUCTURING ACTIVITIES - Co attributes improved net loss margin to restructuring activities aimed at optimizing organization

ACQUISITION EXPENSES - Transaction costs related to strategic portfolio evaluation impacted financial results

CURRENCY IMPACT - Constant currency sales decline of 2.1% due to foreign exchange rates

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$116.70 mln
$112.80 mln (2 Analysts)
Q2 Adjusted EPS
Beat
$0.26
$0.21 (2 Analysts)
Q2 EPS
-$0.14
Q2 Adjusted Net Income
Beat
$7.20 mln
$5.80 mln (1 Analyst)
Q2 Adjusted EBITDA
Beat
$17.50 mln
$17.10 mln (3 Analysts)
Q2 Adjusted EBITDA Margin
15.0%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for ZimVie Inc is $16.00, about 17.6% below its July 29 closing price of $18.81

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nGNX5xN9Pp

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)